Xenetic Biosciences Holds Successful Annual Meeting with StockholdersOn December 11, 2024, Xenetic Biosciences, Inc. (NASDAQ: XBIO) conducted its 2024 Annual Meeting of Stockholders, as documented in an 8-K filing with the U.S. Securities and Exchang

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Xenetic Biosciences’s 8K filing here.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.